AKT1 and diabetes mellitus: We previously reported that EPO inhibited oxidative stress and inflammation in the vasculature and kidneys in animal models of hypertension, diabetes, and chronic kidney disease beyond its hematopoietic effects, and that activation of the PI3K/Akt pathway would be the pivotal mechanism of the tissue protective effects of EPO [7,8,9,10,11].